Educational information, not medical advice; pending clinical review.

Patient guide

Med spa safety: what the name means, and how to check

A med spa is a business that sells cosmetic medical procedures in a spa-like setting. The words med spa are not a license. This page explains how to look up the person who would treat you, what to look for on a vial or box, how to report a problem, and what FDA, CDC, and state sources say about common treatments.

State rules change. The state descriptions below follow official pages linked here, from research compiled on November 13, 2026. Confirm the current text on the official page before you rely on it. A listing on Medical Spa Locator is not a license check. Read what Human Verified does and does not check.

What a med spa is, and what the name is not

In everyday use, a med spa offers procedures such as injections, lasers, peels, and other cosmetic treatments in a setting that looks more like a spa than a hospital. The procedures that affect living tissue are still medical procedures. The setting does not change that.

The name is not a credential. The American Society of Plastic Surgeons says the use of the term med spa is not regulated by a single oversight organization, and that a medical director may legally be a physician from almost any specialty. The New York Department of State consumer page notes that there is no single New York agency that licenses med spa providers as a category.

There is no single federal med spa license. FDA oversees drugs and devices, not spa licenses. CDC investigates some outbreaks. The FTC takes reports about advertising. Licensing, ownership, supervision, and most complaints sit with state boards, and those boards do not all use the same rules.

The American Society for Dermatologic Surgery Association has published a model Medical Spa Safety Act. That is advocacy for state legislatures. It is not a law that applies in every state. The American Medical Association has likewise urged states to require an on-site, trained supervising physician. Those positions are advocacy, not a description of current law everywhere. The AMA's October 6, 2025 article asks who is actually on site.

Red flags

These are points official or professional sources tell patients to notice. One of them is a reason to slow down and ask questions. It is not, by itself, a diagnosis of what happened to a particular person.

  • The injection is offered in a home, hotel room, party, or other non-health-care setting. CDC's 2024 investigation of harmful botulinum toxin reactions reported injections by unlicensed or untrained people, or in non-health-care settings including homes and spas. CDC's advice is to receive injections only from licensed, trained professionals, in a licensed or accredited health care setting, using FDA-approved product from an authorized source. CDC Health Alert, April 23, 2024.
  • The business will not name the medical director, or the director's credentials are not easy to find. ASPS describes that as a red flag. ASPS, July 8, 2024.
  • Supervision is a name on a website only. The Medical Board of California tells consumers to ask whether the physician is immediately reachable or the arrangement is paper-only. Medical Board of California.
  • The price is far below a typical physician-office price. The California board's example is an injection advertised for $50 when the going rate at a physician's office is $500. The board says that is a reason to doubt the product is genuine. That example is the board's illustration, not a price measured by Medical Spa Locator.
  • Staff will not show the carton or vial, will not say where the product came from, or the product came from an online marketplace or an unlabeled vial. ASPS, in its April 23, 2024 patient-safety reminder, calls hesitation to say where the product was purchased a red flag. ASPS, April 23, 2024. CDC's December 17, 2024 update says some counterfeit toxin was bought through large online marketplaces rather than authorized suppliers.
  • The visit is high-pressure, or the promises are unrealistic. The California board says to use caution when procedures are marketed that way. Misleading ads can be reported to the FTC.
  • Nobody explains risks, or nobody can say who to call if something goes wrong after you leave. The California board and the FDA filler page both tell patients to know who handles complications.
  • The room is dirty, hands are not washed, gloves are not used, or needles or device tips are reused. The Illinois IDFPR and IDPH memo of October 30, 2025 treats med spas as health care facilities for infection control and points to CDC and OSHA standards.
  • An esthetician or cosmetologist is the person who will inject or use a medical laser. Official Illinois, California, and New York pages say those licenses do not cover those procedures. Details are in the next section.
  • Staff will not state their credentials. Texas requires a name tag, or similar identification, that shows the identity and credentials of a person performing a delegated medical act. 22 Texas Administrative Code section 169.28.

Who should be injecting

Ask who will actually do the procedure. The spa's name, and a medical director listed on the site, are not the same fact. ASPS says to ask what qualifications that person has, how many times they have done this procedure, who trained them, and who is available if something goes wrong. FDA tells people considering dermal fillers to seek a licensed health care provider with experience in dermatology or plastic surgery.

Who may inject, and how close a physician must be, is set by each state and can differ by procedure. The notes below are limited to Illinois, Texas, California, Florida, and New York, because those are the states covered with official sources in the research for this page. If yours is not listed, check your state medical board or nursing board. Do not treat another state's rule as yours.

Illinois

The joint IDFPR and IDPH memo on medical spa services, updated October 30, 2025, is the state's plain-language source. It says physicians licensed to practice medicine in all of its branches may perform cosmetic procedures that affect the living layers of the skin, may prescribe and administer drugs including botulinum toxin and weight-loss medication injections, and may supervise and delegate those procedures within the Medical Practice Act. Delegation has to stay within that physician's own training and within a physician-patient relationship.

The memo says cosmetologists and estheticians are prohibited from any technique, product, or practice intended to affect the living layers of the skin. It points to an IDFPR statement that the following are the practice of medicine and are not within a cosmetologist's or esthetician's scope: botulinum toxin (Botox), chemical peels except superficial peels, collagen injections, colonics, liposuction, microblading, microneedling, and radiofrequency.

The memo says the Medical Practice Act and the Nurse Practice Act require med spas to be owned and operated by physicians, and that for some services they can be owned and operated by an APRN, because the services are medical services. A salon registration cannot be used to operate a med spa. The memo also says salon rules prohibit using "medical" or a similar term in a salon or shop name.

The memo treats FDA-classified medical lasers, and similar light, IPL, and radiofrequency devices used for dermatologic or cosmetic procedures that disrupt the epidermal surface, as the practice of medicine. A physician generally must examine the patient before a laser procedure. Ablative procedures that are delegated require on-site physician supervision. Non-ablative procedures may be delegated with on-site supervision, or with the physician available by telephone or other electronic means to respond promptly. Anyone delegated laser work must have appropriate, documented training on each system.

A change effective January 1, 2025, Public Act 103-814, amended 225 ILCS 60/54.2. An on-site physician examination before a non-ablative laser procedure is not required when all of the following are true: the laser hair removal facility follows a physician delegation protocol available to IDFPR on request; an advanced practice registered nurse performs the examination; a physician delegates the procedure to a registered nurse or licensed practical nurse who has documented training on each system; and a physician is available by telephone or other electronic means to respond promptly. This exception is about that laser-hair-removal setup. It is not a general permission for every cosmetic procedure.

Texas

The Texas Medical Board Bulletin of February 2025 says treatments such as Botox and IV hydration are medical procedures. They must be administered by a Texas-licensed physician or properly delegated to qualified non-physicians under that physician's delegation and supervision. The delegating physician must be trained or familiar with the delegated acts and able to perform them to the standard of care. 22 Texas Administrative Code section 169.26, adopted January 10, 2025, also says that before the act a physician, or a PA or APRN acting under physician delegation, must establish a practitioner-patient relationship. A physician, PA, or APRN must be on site during the procedure or immediately available for emergency consultation.

Section 169.28 requires the delegating physician's name and Texas medical license number to be posted in each public area and treatment room, along with the board's complaint notice. Each person performing a delegated act must be readily identified by a name tag or similar means that shows identity and credentials.

Texas did not enact a statewide medical-spa-director law in 2025. House Bill 3749 was introduced with medical-spa-director language. The enrolled bill, effective September 1, 2025, regulates elective intravenous therapy. Bill history and enrolled text.

California

The Medical Board of California says that if a facility offers medical procedures, it must be owned by physicians, and that med spa is a marketing term. Cosmetologists may perform superficial treatments such as facials and microdermabrasion. They may never inject the skin, use lasers, or perform medical-level dermabrasion or skin peels. The board says those medical treatments must be performed by a physician, or by a registered nurse or physician assistant under the supervision of a physician. The supervising physician does not have to be on site, but must be immediately reachable.

Florida

Florida's statute reviewed for this page does not use the words medical spa. Section 458.348 says protocols for laser or light-based hair removal or reduction by people who are not allopathic or osteopathic physicians must require appropriate training, and that this work may be done only under the direct supervision and responsibility of a physician licensed under chapter 458 or 459.

If a physician supervises an APRN or PA at an office that is not the physician's primary practice, without the physician on site, and the services are primarily dermatologic or skin-care services, including aesthetic skin care other than plastic surgery, the statute requires the physician to be board certified or board eligible in dermatology or plastic surgery. Those offices must be within 25 miles of the primary practice or in a contiguous county. The distance between any of the offices may not exceed 75 miles. The physician may supervise only one such office besides the primary practice, and must post a schedule of hours when the physician is present and when the office is open without the physician. This is a supervision rule for that kind of office. It is not a general statement that only a dermatologist or plastic surgeon may inject.

New York

The New York Department of State says appearance-enhancement services, such as facials and eyelash extensions, can be performed by people with a cosmetology license from the Department of State. It says medical procedures cannot be provided by appearance-enhancement licensees, including cosmetologists and estheticians. The page's list includes injections of any drugs, including Botox, or any fillers, including Restylane, whether by needle or pressure pen; CoolSculpting; cryotherapy; microneedling; laser procedures except laser hair removal; peels; radiofrequency; GLP-1 weight-loss injections; and vitamin infusions, among other items.

The same page says a business offering those procedures, or promoting med spa services, must be licensed as a medical facility or a medical practice, must employ licensed physicians as medical directors, and must be owned and operated by licensed physicians. It also says a professional corporation or professional limited liability company cannot have "spa" in its name. The page's exception for laser hair removal, as distinct from other lasers, was flagged in the research as something to confirm with current state practice guidance before treating it as permission for a particular licensee. This page does not add that permission.

How to check a license

Look up the named person. A clear result is not a guarantee that a procedure is appropriate, and board certification is not the same thing as a state license. A licensed physician is not necessarily certified in dermatology or plastic surgery.

  • Physicians, many states: DocInfo, from the Federation of State Medical Boards. It is only as complete as the participating boards' data.
  • Nurses: Nursys, from NCSBN.
  • Board certification in a specialty: ABMS Certification Matters. The California board also points patients to ABMS.

Illinois

IDFPR covers physicians, nurses, physician assistants, and estheticians and cosmetologists. License lookup. Physician profile search.

California

Physicians: Medical Board license verification. Nurses: Board of Registered Nursing. Physician assistants: Physician Assistant Board. The medical board notes that the PA board site moved to pab.ca.gov.

Texas

Texas Medical Board license lookup.

Florida

Board of Medicine. Provider search help: MQA Search Services. A broader starting point is Florida Health medical quality assurance.

New York

Office of the Professions online verification. The Department of State page above explains which agency licenses appearance-enhancement work versus medical practice.

The same lookup steps, placed next to an explanation of the Human Verified badge, are on the verification page. That badge is not applied to every listing.

Spotting a counterfeit or swapped product

For a botulinum toxin injection, the CDC prevention page tells patients to watch the labeled vial being drawn and to ask whether the product is an FDA-approved product from an authorized supplier, not an online marketplace or an unlabeled vial. CDC's public line is: "If in doubt, don't get the injection."

FDA's alert of April 16, 2024, updated May 1, 2024, "Counterfeit Version of Botox Found in Multiple States", describes signs of that counterfeit version. Any one of these was enough for FDA's description: lot number C3709C3 on the carton and vial; the active ingredient listed as "Botulinum Toxin Type A" instead of "OnabotulinumtoxinA"; a 150-unit dose, which FDA said is not a unit made by AbbVie or Allergan; or carton language that is not English. FDA says authentic FDA-approved Botox displays OnabotulinumtoxinA, comes in 50-, 100-, and/or 200-unit presentations depending on the product, and identifies the manufacturer as Allergan Aesthetics, AbbVie, Allergan, or abbvie. FDA said there was no indication the reported events were linked to AbbVie's authentic product.

Official counts from that period are not one number. Keep the dates attached.

  • As of April 15, 2024, the CDC newsroom notice of April 16 reported 19 people in 9 states, 9 hospitalized, 4 treated with botulism antitoxin, and no deaths.
  • As of April 18, 2024, the CDC Health Alert of April 23 reported 22 people in 11 states: California, Colorado, Florida, Illinois, Kentucky, Nebraska, New Jersey, New York City, Tennessee, Texas, and Washington. All were reported as females aged 25 to 59. All reported injections by unlicensed or untrained individuals or in non-health-care settings, including homes or spas. Of 20 people with information, 11 were hospitalized. None met the case definition for botulism, and none had died.
  • The CDC outbreak page, Fast Facts updated December 17, 2024, lists 17 cases, 13 hospitalizations, 0 deaths, and 9 states. That update says the formal investigation is closed and that CDC continued to receive reports of similar cases, including at least four harmful reactions in August and September linked to counterfeit botulinum toxin products. Some products were self-injected. Some were purchased through large online marketplaces.

Brands of botulinum toxin are not interchangeable. Botox Cosmetic labeling says its units are specific to its preparation and cannot be compared with or converted into units of any other botulinum toxin product. The same kind of warning is on the Dysport, Xeomin, Jeuveau, and Daxxify labels.

For fillers, the FDA filler page says to use FDA-approved fillers, not to buy filler sold for the public to inject, and not to use needle-free devices. FDA says injectable silicone is not approved for any aesthetic procedure. The FDA consumer update on dermal fillers tells patients to ask for sealed, labeled, FDA-approved product and not to buy filler sold directly to the public.

Suspected counterfeit product can be reported to FDA at 800-551-3989 or on the Report Suspected Criminal Activity form, even if nobody was injured. Harmful reactions also go to MedWatch, in the next section.

How to report a spa

Match the problem to the office. A license concern, an infection, a drug or device reaction, a counterfeit vial, and a misleading ad can go to different places. You can file more than one report. A state board can investigate licensure and standard-of-care issues. It generally does not award money. MedWatch does not discipline a spa or issue a refund.

If symptoms are an emergency, get medical care first. For botulinum toxin, CDC lists blurry or double vision, drooping eyelids, difficulty swallowing or breathing, and muscle weakness, hours to weeks later, and says not to wait. The April 23, 2024 Health Alert and the FDA counterfeit alert also list dry mouth, slurred speech, and weakness. For filler, FDA says to seek immediate medical attention for unusual pain, vision changes, white or gray or blue skin near the injection, or signs of stroke during or shortly after the procedure. Reporting does not replace that care. The CDC clinical botulism line, 770-488-7100, is for clinicians and health departments, 24 hours a day.

Illinois

Physicians, nurses, physician assistants, estheticians, and other professions licensed through IDFPR: file a complaint. Complaint Intake Unit, 555 West Monroe Street, 5th Floor, Chicago, IL 60661. Email FPR.CIU@illinois.gov. Phone (312) 814-6910. Toll-free 1-888-473-4858. The complaint page says complaint and investigation files are confidential under 20 ILCS 2105/2105-117, with limited exceptions.

For an infection, an outbreak, or unsanitary conditions, contact the local health department. The October 30, 2025 memo cites this directory: Illinois regional health departments. The memo says med spa staff are designated reporters of unusual infectious conditions and outbreaks under state communicable-disease rules. That reporting duty is for staff. A patient report to the health department is a separate step, and it is in addition to a board complaint.

California, Texas, Florida, and New York

If you were treated in another state, start with the board that licenses the person who treated you. This page does not link an unofficial 50-state complaint directory.

FDA, counterfeit product, and advertising

  • Harmful reactions, quality problems, and medication errors, including compounded semaglutide: MedWatch. Online form: voluntary reporting. Phone 1-800-FDA-1088. Fax 1-800-FDA-0178.
  • Suspected counterfeit Botox, even if nobody was injured: 800-551-3989, or the suspected criminal activity form.
  • Misleading ads, including a claim that a compounded drug is the same as an approved drug, or a guarantee of results: FTC ReportFraud. The FTC does not generally resolve an individual refund the way a court might.

A practical checklist that includes these reporting steps is also on how to choose a med spa.

Safety notes by treatment

These are cited notes, not a statement that a treatment is safe or unsafe for a particular person. They do not include doses. "FDA cleared," which is common for devices, is not the same phrase as "FDA approved," which is used for drugs and for many filler implants. Registration or listing alone is not approval or clearance.

Botulinum toxin

Botox Cosmetic, Dysport, Xeomin, Jeuveau, and Daxxify are FDA-approved prescription products. Each label has its own indications. Do not assume every brand is approved for every facial site. Units cannot be converted from one brand to another.

The products carry a boxed warning that effects can spread from the injection area and cause weakness, double vision, drooping eyelids, trouble swallowing, voice changes, trouble speaking, loss of bladder control, and breathing difficulty. Symptoms have been reported hours to weeks later. Swallowing and breathing problems can be life-threatening, and deaths have been reported. Botox Cosmetic labeling also says that, for its labeled dermatologic doses for frown lines, crow's feet, forehead lines, and platysma bands, no definitive serious distant-spread cases have been reported at those labeled doses. The boxed warning still applies to the product class, including unapproved uses.

In Botox Cosmetic trials cited on the label, eyelid ptosis was reported in 3 percent of glabellar-line patients (13 of 405) and in 0 percent with placebo. In forehead-line studies, headache was reported in 9 percent versus 5 percent with placebo, and eyelid ptosis and brow ptosis were each reported in 2 percent. Those are trial figures, not a prediction for one person.

Labeling lists known hypersensitivity to any botulinum toxin product or to a component, and infection at the injection site, as contraindications. It says there are no adequate data on use in pregnancy, and that it is not known whether the drug passes into breast milk. An FDA consumer page says cosmetic botulinum toxin is not recommended while pregnant or lactating. Safety and effectiveness for cosmetic use have not been established in pediatric patients. Seek medical care for trouble swallowing, speaking, or breathing, spreading weakness, vision changes, or allergic symptoms such as wheezing, swelling, or feeling faint. Source: Botox Cosmetic labeling.

Dermal fillers

FDA-approved dermal fillers are implants approved for specific uses. Approved uses in adults 22 or older depend on the product. FDA recommends against using fillers to enlarge breasts or buttocks, to add fullness to the feet, to implant into bone, tendon, ligament, or muscle, or to inject the glabella, nose, periorbital area, forehead, or neck. Those uses are not FDA approved. Needle-free devices are not approved for filler. No dermal filler is approved for sale over the counter. Injectable silicone is not approved for any aesthetic procedure.

Common effects listed by FDA include bruising, redness, swelling, pain, tenderness, itching, and rash. Less common or rare events reported to FDA include infection, nodules, tissue death, allergic reaction, vision problems including blindness, stroke, and death. Unintentional injection into a blood vessel can block blood flow. FDA has said the chance is low and the harm can be permanent. FDA says to seek immediate medical attention for unusual pain, vision changes, white, gray, or blue skin, or stroke signs such as sudden trouble speaking, face drooping, weakness, trouble walking, severe headache, dizziness, or confusion.

FDA says safety is unknown in pregnancy, while breastfeeding, under age 22, and in people prone to keloids or thick scars. Hyaluronic-acid filler can often be reduced with hyaluronidase. Many non-hyaluronic-acid fillers cannot. FDA has said no hyaluronidase product is approved specifically for dissolving hyaluronic-acid filler, even though hyaluronidase products are approved for other uses and are used for this purpose. The ASDS task force recommends that a clinic injecting hyaluronic-acid filler have a complication plan and hyaluronidase on hand. This page does not describe doses or a treatment protocol. Source: FDA dermal fillers.

Sculptra, Radiesse, and Skinvive

Sculptra (poly-L-lactic acid) is an FDA-approved implant. A supplement approved April 25, 2023, expanded use to fine lines and wrinkles in the cheek in immune-competent people. The supporting study described results lasting up to 24 months. Sculptra labeling warns that injection into a blood vessel can cause vision loss, stroke, and skin necrosis, and it describes delayed papules, nodules, and granulomas. It should not be used in people with hypersensitivity to a component, severe allergies with anaphylaxis, a history of keloids or thick scars, or, when lidocaine is added, an allergy to lidocaine. Hyaluronidase does not dissolve poly-L-lactic acid.

Radiesse (calcium hydroxylapatite) is a different FDA-approved implant, not hyaluronic acid. Its labeling likewise warns that injection into a blood vessel can cause vision loss, stroke, and necrosis, and it lists severe allergy, hypersensitivity, and bleeding disorders among contraindications. Hyaluronidase does not dissolve it. Check the current instructions for the exact approved site.

Skinvive by Juvéderm is an FDA-approved hyaluronic-acid gel. A supplement approved May 11, 2023, is for intradermal injection to improve cheek smoothness in adults 21 and older. In the supporting study of 209 people, the smoothness effect lasted at least six months. It carries the same kind of vessel, allergy, and inflammation risks as other hyaluronic-acid fillers. FDA's approval summary says it should not be used in people with severe allergies and a history of anaphylaxis, multiple severe allergies, allergy to gram-positive bacterial proteins, or allergy to lidocaine. This note uses the May 2023 cheek indication. It does not describe later sites.

Microneedling and radiofrequency microneedling

FDA has authorized specific microneedling devices for limited uses, such as facial acne scars, facial wrinkles, and abdominal scars, in patients 22 and older. Authorized sites depend on the device. Those devices are not approved to deliver cosmetics, topical drugs, vitamin solutions, or blood products such as PRP into the skin. Common short-term effects on the FDA microneedling page include dryness, redness, itching, peeling, bruising, and crusting. Less common effects include pigment change, cold-sore reactivation, infection, and scarring. FDA says to use a new cartridge for every patient and every session, and not to reuse cartridges.

The American Academy of Dermatology says professionally performed microneedling can be used on all skin tones, and that at-home or non-medical devices can infect, scar, or change color if they pierce the skin or are overused. FDA and AAD give different waiting periods after isotretinoin. This page does not pick one. A clinician has to reconcile that before treating.

Radiofrequency microneedling devices are a different category. They are Class II devices cleared through 510(k). On October 15, 2025, FDA warned of serious complications with certain aesthetic uses, including burns, scarring, fat loss, disfigurement, and nerve damage, sometimes needing surgery or other care. FDA did not publish a complication rate in that communication. FDA says this is a medical procedure, not a home cosmetic treatment. Seek care for burns, unexpected hollowing, numbness, weakness, or wounds.

Lasers, IPL, and chemical peels

Many lasers and intense pulsed light devices are FDA-cleared for specific uses. Clearance of a device is not a statement about every setting or every skin tone. The AAD laser hair-removal FAQ says the most common effects are discomfort, swelling, and redness lasting 1 to 3 days, and that blistering, infection, scarring, and lasting color change are possible. AAD says laser hair removal can be dangerous in inexperienced hands, and that darker skin is more prone to burns and dark marks. AAD recommends a board-certified dermatologist with experience treating darker skin when lasers are used. Everyone in the room needs eye protection. AAD on lasers and skin.

On July 30, 2024, FDA said it has not approved any chemical peel products, and that high-concentration acids sold for unsupervised use can cause severe burns, swelling, infection, color change, and scars. The AAD peel FAQ says results depend largely on the skill of the person performing the peel, and that people with skin of color should see a dermatologist with experience using peels on darker skin. AAD says that without that knowledge, permanent pigment problems can occur. AAD describes a deep peel as a procedure done in a surgical setting.

HydraFacial

HydraFacial is a brand of hydradermabrasion system, not an FDA-approved drug and not a filler implant. FDA registration or listing is not approval or clearance. The research for this page did not find an FDA safety communication specific to the brand, and it did not find a published complication rate to quote. Ask who is performing the service, whether a new tip is used for each person, and how the handpiece and fluids are handled. The FDA device pages linked above tell patients to ask those cleaning questions about devices that touch the skin. Seek care for spreading redness, pus, fever, or significant pain.

Body contouring and CoolSculpting

The FDA body-contouring page says cryolipolysis devices, including prescription fat-freezing systems such as CoolSculpting, are authorized to reduce small fat bulges. They are not treatments for obesity or for weight loss. FDA says there are no FDA-cleared or approved non-invasive body-contouring devices for treating the breasts. Common effects can include redness, bruising, swelling, pain, and temporary color change.

Paradoxical adipose hyperplasia is a fat-freezing effect in which the treated fat grows instead of shrinking. FDA describes a firm bulge, often the shape of the applicator, usually appearing two to five months later. It does not go away on its own and may require surgery, which may not fully correct it. The manufacturer's safety information reports a post-marketing rate of about 1 in 3,000 treatments (0.033 percent). That figure is calculated from reported events and treatment cycles and may not capture every case. CoolSculpting important safety information.

FDA says not to have fat freezing with cold-sensitivity disorders, including Raynaud's disease, cold urticaria, cryoglobulinemia, cold agglutinin disease, paroxysmal cold hemoglobinuria, or poor circulation in the area, and not to treat over a hernia or a weak abdominal wall. Seek care for severe or worsening pain, blistering, signs of a hernia, or a firm, growing, often rectangular bulge months later.

IV drips

A compounded "wellness," vitamin, or glutathione infusion is generally not an FDA-approved drug. On August 27, 2026, FDA reported at least 30 patients with adverse events after IV glutathione, alone or with other ingredients, compounded by pharmacies that had obtained dietary-supplement-grade glutathione, Medisca lot number 229536. Two Texas pharmacies recalled products for elevated endotoxin. Reported events included fever, chills, pain, dizziness, signs of shock, and sepsis-like symptoms, with some hospitalizations. FDA says dietary-supplement-grade glutathione should not be used to compound injectables. Seek emergency care for fever, chills, dizziness, severe pain, low blood pressure, confusion, shortness of breath, or sepsis-like symptoms during or after an infusion.

CDC injection-safety guidance for health care settings says to use a new sterile needle and syringe for every injection and not to reuse single-dose vials. This page does not quote a rate for ordinary IV-vitamin side effects, because the research did not find one to cite.

GLP-1 and semaglutide medicines

Wegovy, Ozempic, and Rybelsus are FDA-approved semaglutide products with different labeled uses. Wegovy's labeling, on DailyMed, includes a boxed warning that semaglutide caused thyroid C-cell tumors in rodents. It is not known whether it does so in people. Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. Common effects named on the label include nausea, diarrhea, vomiting, constipation, and abdominal pain. Serious labeled risks include pancreatitis, gallbladder disease, low blood sugar when combined with certain diabetes drugs, kidney injury from dehydration, severe stomach reactions, allergic reactions, and a risk of food entering the lungs under anesthesia because the drug slows the stomach. For weight-loss use, the label says to stop when pregnancy is recognized and at least two months before a planned pregnancy. This page does not give doses.

Compounded semaglutide and compounded tirzepatide are not those approved products. FDA says compounded drugs should be used only when an approved drug cannot meet a patient's need. As of May 31, 2026, FDA reported 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, with likely underreporting, and says a report does not always establish the cause. FDA GLP-1 concerns.

A July 29, 2024 FDA alert describes dosing errors with compounded injectable semaglutide, including people giving themselves five to 20 times the intended dose after mixing up milliliters, milligrams, and units. Some people were hospitalized. FDA has also warned about salt forms, extra unstudied ingredients, vials kept in use more than 28 days after the first puncture, product that arrives warm, and products labeled for research or not for human consumption that are sold with dosing instructions. Claims that a compounded product "is" Ozempic or Wegovy are false or misleading, according to FDA. Seek care for severe persistent abdominal pain, with or without vomiting, especially pain that spreads to the back, and for signs of an allergic reaction or a neck mass with trouble swallowing or persistent hoarseness.

PRP and vampire facials

FDA-authorized microneedling devices are not approved to deliver PRP into the skin. In the MMWR of April 25, 2024, CDC and the New Mexico Department of Health described likely HIV transmission associated with PRP microneedling at an unlicensed spa. Inspection found unlabeled blood tubes stored with food, unwrapped syringes in ordinary trash, no autoclave, and disposable tips that were reused. Expected local effects of a blood draw plus needling include temporary redness, swelling, and bruising. This page does not invent an efficacy rate. Seek care for fever, spreading redness, or pus, and talk with a clinician about testing if a facility's infection control is later questioned.

Common questions

Are med spas safe?+

The name does not answer that. The American Society of Plastic Surgeons says the term med spa is not regulated by a single oversight organization. Whether a particular visit is appropriate depends on the product, the license and training of the person doing the procedure, infection control, and the setting. This page explains how to check those things. It is not a judgment about a particular spa, and it is not medical advice.

Is med spa a license or a credential?+

No. The American Society of Plastic Surgeons says use of the term med spa is not regulated by a single oversight organization. The New York Department of State consumer page notes that there is no single New York agency that licenses med spa providers as a category. A business can use the words without those words themselves being a license.

Are med spas regulated?+

There is no single federal med spa license. FDA, CDC, and FTC do not license med spas. State medical, nursing, physician assistant, and cosmetology boards license people and, in some states, set ownership and supervision rules. Those rules are not the same in every state.

Who can inject Botox or dermal fillers?+

It depends on the state and on the kind of license. There is no single national list. In California, the Medical Board says medical treatments must be performed by a physician, or by a registered nurse or physician assistant under physician supervision, and that cosmetologists may never inject the skin. In Illinois, the October 30, 2025 IDFPR and IDPH memo says cosmetologists and estheticians may not use techniques intended to affect the living layers of the skin, and it lists botulinum toxin among practices outside that scope. Check the license of the person who will inject you with the board that licenses that person.

Can an esthetician or cosmetologist inject Botox?+

Not under the official Illinois, California, or New York materials summarized on this page. Illinois and California say those licenses do not authorize injections. New York’s Department of State says appearance-enhancement licensees, including cosmetologists and estheticians, cannot provide the medical procedures on its list, and that list includes injections of any drugs, including Botox, or any fillers. Other states need their own board rules. A physician’s name on a website does not by itself change the scope of an esthetician license.

Does a physician have to be in the room?+

State rules differ, and they can differ by procedure. California’s Medical Board says the supervising physician does not have to be on site but must be immediately reachable, and it tells consumers to ask whether supervision is real or paper-only. Texas rules effective in January 2025 say a physician, physician assistant, or advanced practice registered nurse must be on site during the delegated procedure or immediately available for emergency consultation. Illinois treats ablative laser delegation differently from non-ablative laser delegation. This page does not turn those examples into a rule for every state.

How do I check a doctor or nurse license?+

Look up the person who will treat you, not only the spa. For a physician, the Federation of State Medical Boards DocInfo tool covers many state licenses, and each state board has its own lookup. For a nurse, NCSBN Nursys covers compact and many non-compact licenses. Board certification, which ABMS Certification Matters can show, is not the same thing as a state license. A clear search is not a guarantee of safety. This page lists Illinois, California, Texas, Florida, and New York starting points.

How do I check a Botox vial or box?+

The CDC says to watch the labeled vial being drawn and to ask whether the product is FDA-approved and came from an authorized source. FDA’s April 16, 2024 alert, updated May 1, 2024, described signs of a counterfeit version: lot number C3709C3 on the carton and vial; the active ingredient listed as Botulinum Toxin Type A instead of OnabotulinumtoxinA; a 150-unit dose; and carton language that is not English. FDA says authentic FDA-approved Botox displays OnabotulinumtoxinA, comes in 50-, 100-, and/or 200-unit presentations, and names the manufacturer as Allergan Aesthetics, AbbVie, Allergan, or abbvie. If you cannot see the carton and vial, CDC’s public advice is: “If in doubt, don’t get the injection.”

What symptoms after a botulinum toxin injection does the CDC say need emergency care?+

The CDC lists blurry or double vision, drooping eyelids, difficulty swallowing or breathing, and muscle weakness, and says these can appear hours to weeks after injection and not to wait. The CDC Health Alert of April 23, 2024, and the FDA counterfeit-Botox alert also list blurred or double vision, drooping eyelids, trouble swallowing or breathing, dry mouth, slurred speech, and weakness, and say to get emergency care. Reporting the product to FDA does not replace emergency care.

How do I report a med spa in Illinois?+

For a physician, nurse, physician assistant, esthetician, or other profession licensed through the Illinois Department of Financial and Professional Regulation, file a complaint at the IDFPR complaint page or call the Department complaint line, (312) 814-6910. The complaint intake unit is at 555 West Monroe Street, 5th Floor, Chicago, IL 60661. Email FPR.CIU@illinois.gov. Toll-free 1-888-473-4858. For an infection, outbreak, or unsanitary conditions, also contact the local health department. A licensing complaint does not award money and does not replace medical care.

How do I report a med spa in California, Texas, Florida, or New York?+

Use the board that licenses the person who treated you. California physicians: the Medical Board of California complaint page. California nurses: the Board of Registered Nursing. California physician assistants: the Physician Assistant Board. Texas physicians and other Texas Medical Board licensees: the TMB place-a-complaint page. Florida: the MQA online complaint portal or the Board of Medicine. New York professional licenses: the Office of the Professions discipline complaint form. Appearance-enhancement issues in New York may also go to the Department of State. Links are in the reporting section of this page. If you are in another state, start with that state’s medical board. This page does not publish a 50-state complaint directory.

How do I report counterfeit Botox or a harmful reaction?+

These are separate reports. A harmful reaction to a drug or device, including a filler, toxin, or compounded drug, can go to FDA MedWatch at 1-800-FDA-1088 or the online voluntary form. Suspected counterfeit product can be reported to FDA at 800-551-3989 or on the FDA Report Suspected Criminal Activity form, even if nobody was injured. The license of the person who injected goes to the state board. Misleading advertising can go to the FTC at ReportFraud. A board complaint does not refund a patient, and MedWatch does not discipline a spa.

Is compounded semaglutide the same as Ozempic or Wegovy?+

No. FDA says compounded drugs are not FDA-approved and do not go through FDA premarket review for safety, quality, or effectiveness. FDA has said claims that a compounded product is Ozempic or Wegovy, or is the same as the approved drug, are false or misleading. Wegovy and Ozempic are different FDA-approved semaglutide products with their own labeled uses. As of May 31, 2026, FDA reported 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. FDA says a report does not prove the drug caused the event, and that events are likely underreported.

What did CDC report about vampire facials and HIV?+

In an MMWR report dated April 25, 2024, CDC and the New Mexico Department of Health described the first documented cluster of likely HIV transmission associated with cosmetic injection services: platelet-rich plasma with microneedling, sometimes called a vampire facial, at an unlicensed spa. The inspection found unsafe infection-control practices. FDA-authorized microneedling devices are not approved to deliver blood products such as PRP into the skin. This is a description of that investigation, not a risk number for every spa.

Related guides

These pages answer different questions. Choosing a clinic, reading what a badge means, and comparing a med spa with a dermatologist or plastic surgeon are separate from this safety guide.